1. Home
  2. SY vs GLSI Comparison

SY vs GLSI Comparison

Compare SY & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SY

So-Young International Inc. American Depository Shares

HOLD

Current Price

$2.16

Market Cap

192.7M

Sector

Technology

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$14.65

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SY
GLSI
Founded
2013
2006
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.7M
187.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SY
GLSI
Price
$2.16
$14.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.50
$50.00
AVG Volume (30 Days)
205.3K
152.5K
Earning Date
05-15-2026
05-19-2026
Dividend Yield
0.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.64
N/A
Revenue Next Year
$30.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.28
$7.78
52 Week High
$5.35
$34.10

Technical Indicators

Market Signals
Indicator
SY
GLSI
Relative Strength Index (RSI) 64.48 38.87
Support Level $1.68 $12.51
Resistance Level $2.15 $29.89
Average True Range (ATR) 0.16 1.40
MACD 0.03 0.29
Stochastic Oscillator 80.46 36.89

Price Performance

Historical Comparison
SY
GLSI

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Share on Social Networks: